Page 2 - High Blood Pressure

Granules gets USFDA nod to market generic medicine for high blood pressure

Drug firm Granules India on Monday said it has received approval from the US health regulator to market a generic product to treat high blood pressure. The company has received approval from the US Food & Drug Administration (USFDA) to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg, Granules India said in a regulatory filing. The Hyderabad-based company's product is bioequivalent to the Organon LLC's Cozaar tablets. According to IQVIA/IMS Health, the current annual US market for Losartan potassium tablets is around USD 336 million. Shares of the company were trading 1.24 per cent down at Rs 281.75 apiece on the BSE.

India lacks adequate community level data for hypertension control: Lancet

More than 50 per cent of patients in India are unaware of their high blood pressure, finds a study published in Lancet Regional Health Journal

Lupin receives tentative USFDA nod for generic Azilsartan Medoxomil tablets

The tentative approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) Azilsartan Medoxomil tablets is for strengths of 40 mg and 80 mg

Unichem, Lupin recall high blood pressure drugs from US over quality issues

The specified batch, which is being recalled, has been manufactured at Unichem's Goa-based facility

High blood pressure in midlife tied to later dementia

Women who were hypertensive at an average age of 44 had a 68% higher risk for dementia than those who had normal blood pressure at that age

High blood pressure drug could treat skin cancer

Drug carvedilol can protect against the sun-induced cell damage that leads to skin cancer

A new 100% effective drug to control high BP: Report

As many as 100% of patients on trial saw their blood levels drop below 140 over 90